APCCC 2024: Escalation Strategies in Patients with mHSPC and an Unfavourable PSA Decline – Is More Better?
APCCC 2024, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), Escalation Strategies in Patients with mHSPC, Unfavourable PSA Decline, PSA progression, radiographic progression, clinical progression, CHAARTED data, LATITUDE trial, Titan Trial, STAMPEDE data.